In response to the viral gastroenteritis epidemic decimating dog breeding, we create the first parvovirus-based vaccine approved for dogs, thus entering the very exclusive club of innovative vaccine-developing laboratories.
The opening of our first subsidiary in Germany, following acquisition of local distributor VMG, marks the beginning of our deployment in Europe.
Number-two French animal health laboratory, we start to trade on the secondary market of the Paris stock exchange.
By designing the first genetically engineered vaccine against feline leukemia made from a purified p45 FeLV-envelope retrovirus, we provide veterinarians with an effective solution against a disease in cats for which there was no cure at the time.
Our founder Pierre-Richard Dick, doctor of veterinary medicine, dies suddenly at the age of 55 while on a Central American sea voyage. Pascal Boissy, then financial director, succeeds him to head the company. Six months later, we adopt a new organizational structure made up of an executive board and a supervisory board, of which Jeanine Dick, wife of the founder, becomes chairwoman.
We push our international expansion further with the creation of our first subsidiary in Asia (a partnership with Maruyasu, a Japanese import-export company).
Numerous companies created to develop the company on French territory merge into a single subsidiary, Virbac France, formalizing the beginning of the Virbac umbrella brand.
Through its “I love my pet, I vaccinate it” poster campaign, we raise the general public’s awareness of vaccination in France.
Eric Marée, 48岁，HEC毕业生，美国康奈尔大学工商管理硕士，现任维克执行董事会主席。
Eric Marée, 48 years old, graduate of HEC and holder of an MBA from Cornell University in the United States, becomes chairman of the Virbac executive board.
Thanks to the acquisition of Agri-Nutrition, a company based in St. Louis (Missouri), we acquire a range of dental care and hygiene products.
We make available to European veterinarians the first interferon omega for dogs and cats.
皮埃尔-理查德·迪克基金会（Pierre-Richard Dick Foundation）Pierre-Richard Dick Foundation成立于1993年，它在创始人去世后更改为维克企业基金会（Virbac Corporate Foundation）。该项目由他的儿子约翰-皮埃尔·迪克（Jean-Pierre Dick）担任主席，旨在提高公众意识，教育并告知（特别对于儿童），在城市中动物健康及人与动物相处的相关问题。
The Pierre-Richard Dick Foundation, created in 1993 after our founder’s death, becomes the Virbac Corporate Foundation. It aims to raise public awareness, educate and inform, especially children, about issues related to the integration and well-being of animals in cities.
We partner with Jean-Pierre Dick, son of our founder and doctor of veterinary medicine, on his sailing adventure: through his involvement in epic races, the skipper helps to enhance the veterinary profession, promote animal health and our values in the four corners of the world.
We strengthen our presence with Indian veterinarians and farmers thanks to the acquisition of Agrivet Farm Care, the animal health branch of GlaxoSmithKline. A collaboration that allows us to become number 1 in this country.
With 7 production units, we currently have an industrial park on five continents (France, United States, Mexico, Brazil, Australia, South Africa and Vietnam) to bring our health solutions ever closer to those who care for animals.
We share with veterinarians the first deslorelin-based implant, inducing a reversible neutering in male dogs.
Committed to the animal proteins of the future, we acquire a majority share of Centrovet, animal health market leader in Chile, expert in the development and production of innovative products for the protection and treatment of cold water aquaculture farms (salmon and trout).
We acquire Schweitzer Biotech Company, a Taiwanese company that is an expert in the development of cell culture banks serving as the basis for production of viral vaccines primarily for swine and poultry. This acquisition gives the impulse to the creation of a new biology R&D structure in Southeast Asia, a region recognized for the largest swine and aquaculture (warm water) markets on the planet.
The Virbac Corporate Foundation, aware of the challenges related to the interconnection between animal, human, and environmental health, initiates support for a screening, control, and prevention program for bovine tuberculosis and rabies in the Gonarezhou Park (Zimbabwe).
After the construction of VB8 in Carros in 2014, a production building dedicated to the manufacture of sterile injectables, Virbac continues to invest in quality and to strengthen its production capacities with Argo Navis, VB8’s alter ego in Mexico.
After the physiological range in 2016, we provide dog and cat owners with a range of dietetic petfood. Their composition is particularly suited to the dietary needs of carnivores.
At the helm of St. Michel-Virbac, Jean-Pierre Dick wins his fourth Jacques Vabre Race (a first in the history of the Coffee Race). This victory marks a turning point in the life of the sailor and the most fitting closure to his 17 years of adventures around the world, flying the colors of our company.
In September, we celebrate our 50th anniversary. Along with the family of our founder, nearly 3,000 connected employees share in a two-day event that unfolds in an atmosphere of warmth, intercultural sharing and engagement in the service of animal health.
We make a jump in several Asian countries thanks to a preventive solution against porcine circovirus, a virus responsible for significant losses in farms. Developed by our teams with the genotype predominant in most regions of the world, this vaccine helps limit the impact of this disease in one of the world's most important swine production areas.
We offer to the European and North American veterinarians the first intratumoral injectable for canine mastocytomas, the second most frequently diagnosed cancer and the most common skin cancer. With this novel injectable solution, we are opening a new path in the treatment of canine skin tumors.
Legal notice All medicines or products mentioned in this document can be not authorized or not marketed in all the countries including France. The product names stated in this document are subject to protection in particular in respect of trademarks. Virbac and/or its subsidiaries are the owners or have exclusive use of them.